A Screen-and-Treat Strategy Targeting Visceral Leishmaniasis in HIV-Infected Individuals in Endemic East African Countries: The Way Forward?

PLoS Neglected Tropical Diseases

Volumn 8, Issue 8, 2014, Pages

  van Griensven, Johan ^a   Diro, Ermias ^a,b   Lopez Velez, Rogelio ^c   Ritmeijer, Koert ^d   Boelaert, Marleen ^a   Zijlstra, Ed E ^e   Hailu, Asrat ^f   Lynen, Lutgarde ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF GONDAR   (Ethiopia)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e Rotterdam Centre for Tropical Medicine   (Netherlands)

^f ADDIS ABABA UNIVERSITY   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMITRIPTYLINE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; FEXINIDAZOLE; FLUCONAZOLE; IMIPRAMINE; ISONIAZID; ITRACONAZOLE; MILTEFOSINE; PAROMOMYCIN;

ANTIBODY RESPONSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG RESISTANCE; EAST AFRICAN; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFUSION RELATED REACTION; INTERFERON GAMMA RELEASE ASSAY; LATEX AGGLUTINATION TEST; LEISHMANIA DONOVANI; LEISHMANIN SKIN TEST; LIVER TOXICITY; MAINTENANCE THERAPY; MIXED INFECTION; MORTALITY; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; OTOTOXICITY; POLYMERASE CHAIN REACTION; PROPHYLAXIS; PROSPECTIVE STUDY; PULMONARY CRYPTOCOCCOSIS; RECURRENCE RISK; RISK FACTOR; SCREENING TEST; SEROLOGY; TOXOPLASMOSIS; TREATMENT FAILURE; TUBERCULOSIS; VISCERAL LEISHMANIASIS; AFRICA; COINFECTION; COMPLICATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEISHMANIASIS, VISCERAL;

AFRICA, EASTERN; CD4 LYMPHOCYTE COUNT; COINFECTION; HIV INFECTIONS; HUMANS; LEISHMANIASIS, VISCERAL; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES;

EID: 84952311289     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003011     Document Type: Article

References (80)

1. van Griensven J, Diro E, (2012) Visceral leishmaniasis. Infect Dis Clin North Am 26: 309–322.
2. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, et al. (2008) The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21: 334–359.
3. Lopez-Velez R, Perez-Molina JA, Guerrero A, Baquero F, Villarrubia J, et al. (1998) Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg 58: 436–443.
4. Pintado V, Martin-Rabadan P, Rivera ML, Moreno S, Bouza E, (2001) Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 80: 54–73.
5. Medrano FJ, Hernandez-Quero J, Jimenez E, Pineda JA, Rivero A, et al. (1992) Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain? AIDS 6: 1499–1503.
6. Montalban C, Calleja JL, Erice A, Laguna F, Clotet B, et al. (1990) Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS. J Infect 21: 261–270.
7. Peters BS, Fish D, Golden R, Evans DA, Bryceson AD, et al. (1990) Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy. Q J Med 77: 1101–1111.
8. Rosenthal E, Marty P, Poizot-Martin I, Reynes J, Pratlong F, et al. (1995) Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans R Soc Trop Med Hyg 89: 159–162.
9. Hurissa Z, Gebre-Silassie S, Hailu W, Tefera T, Lalloo DG, et al. (2010) Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Trop Med Int Health 15: 848–855.
10. Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, et al. (2011) Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis 53: e152–158.
11. ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN, (2008) Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 46: 1702–1709.
12. WHO (2011) Rapid advice: Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-infected Adults, Adolescents and Children. Geneva: Word Health Organization.
13. Rajasingham R, Meya DB, Boulware DR, (2012) Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr 59: e85–91.
14. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, et al. (2011) Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 53: 1019–1023.
15. French N, Gray K, Watera C, Nakiyingi J, Lugada E, et al. (2002) Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 16: 1031–1038.
16. Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, et al. (2007) Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 12: 929–935.
17. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, et al. (2009) Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 48: 856–862.
18. Worodria W, Massinga-Loembe M, Mazakpwe D, Luzinda K, Menten J, et al. (2011) Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. J Acquir Immune Defic Syndr 58: 32–37.
19. Michel G, Pomares C, Ferrua B, Marty P, (2011) Importance of worldwide asymptomatic carriers of Leishmania infantum (L. chagasi) in human. Acta Trop 119: 69–75.
20. Abbasi I, Aramin S, Hailu A, Shiferaw W, Kassahun A, et al. (2013) Evaluation of PCR procedures for detecting and quantifying Leishmania donovani DNA in large numbers of dried human blood samples from a visceral leishmaniasis focus in Northern Ethiopia. BMC Infect Dis 13: 153.
21. Hailu A, Gramiccia M, Kager PA, (2009) Visceral leishmaniasis in Aba-Roba, south-western Ethiopia: prevalence and incidence of active and subclinical infections. Ann Trop Med Parasitol 103: 659–670.
22. Custodio E, Gadisa E, Sordo L, Cruz I, Moreno J, et al. (2012) Factors associated with Leishmania asymptomatic infection: results from a cross-sectional survey in highland northern Ethiopia. PLoS Negl Trop Dis 6: e1813.
23. Gadisa E, Custodio E, Canavate C, Sordo L, Abebe Z, et al. (2012) Usefulness of the rK39-immunochromatographic test, direct agglutination test, and leishmanin skin test for detecting asymptomatic Leishmania infection in children in a new visceral leishmaniasis focus in Amhara State, Ethiopia. Am J Trop Med Hyg 86: 792–798.
24. Ali A, Ashford RW, (1993) Visceral leishmaniasis in Ethiopia. I. Cross-sectional leishmanin skin test in an endemic locality. Ann Trop Med Parasitol 87: 157–161.
25. Singh OP, Hasker E, Yasicin K, Sacks D, Boelaert M, et al. (2014) Asymptomatic leishmania infection: A new challenge for leishmania control. Clin Infect Dis 58: 1424–1429.
26. WHO (2010) Control of the leishmaniasis. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010. WHO technical report series 949. Geneva: World Health Organization.
27. May M, Boulle A, Phiri S, Messou E, Myer L, et al. (2010) Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 376: 449–457.
28. Schaefer KU, Schoone GJ, Gachihi GS, Muller AS, Kager PA, et al. (1995) Visceral leishmaniasis: use of the polymerase chain reaction in an epidemiological study in Baringo District, Kenya. Trans R Soc Trop Med Hyg 89: 492–495.
29. Silva LA, Romero HD, Fagundes A, Nehme N, Fernandes O, et al. (2013) Use of the polymerase chain reaction for the diagnosis of asymptomatic Leishmania infection in a visceral leishmaniasis-endemic area. Rev Inst Med Trop Sao Paulo 55: 101–104.
30. Martin-Sanchez J, Pineda JA, Morillas-Marquez F, Garcia-Garcia JA, Acedo C, et al. (2004) Detection of Leishmania infantum kinetoplast DNA in peripheral blood from asymptomatic individuals at risk for parenterally transmitted infections: relationship between polymerase chain reaction results and other Leishmania infection markers. Am J Trop Med Hyg 70: 545–548.
31. Garcia-Garcia JA, Martin-Sanchez J, Gallego M, Rivero-Roman A, Camacho A, et al. (2006) Use of noninvasive markers to detect Leishmania infection in asymptomatic human immunodeficiency virus-infected patients. J Clin Microbiol 44: 4455–4458.
32. Cota GF, de Sousa MR, Demarqui FN, Rabello A, (2012) The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis. PLoS Negl Trop Dis 6: e1665.
33. Molina I, Fisa R, Riera C, Falco V, Elizalde A, et al. (2013) Ultrasensitive Real-Time PCR for the Clinical Management of Visceral Leishmaniasis in HIV-Infected Patients. Am J Trop Med Hyg 89: 105–110.
34. Orsini M, Canela JR, Disch J, Maciel F, Greco D, et al. (2012) High frequency of asymptomatic Leishmania spp. infection among HIV-infected patients living in endemic areas for visceral leishmaniasis in Brazil. Trans R Soc Trop Med Hyg 106: 283–288.
35. Riera C, Fisa R, Lopez P, Ribera E, Carrio J, et al. (2004) Evaluation of a latex agglutination test (KAtex) for detection of Leishmania antigen in urine of patients with HIV-Leishmania coinfection: value in diagnosis and post-treatment follow-up. Eur J Clin Microbiol Infect Dis 23: 899–904.
36. Diro E, Techane Y, Tefera T, Assefa Y, Kebede T, et al. (2007) Field evaluation of FD-DAT, rK39 dipstick and KATEX (urine latex agglutination) for diagnosis of visceral leishmaniasis in northwest Ethiopia. Trans R Soc Trop Med Hyg 101: 908–914.
37. Lawn SD, (2012) Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis 12: 103.
38. Ates SC, Bagirova M, Allahverdiyev AM, Kocazeybek B, Kosan E, (2013) Utility of the microculture method for Leishmania detection in non-invasive samples obtained from a blood bank. Acta Trop 128: 54–60.
39. Sharma MC, Gupta AK, Das VN, Verma N, Kumar N, et al. (2000) Leishmania donovani in blood smears of asymptomatic persons. Acta Trop 76: 195–196.
40. Maurya R, Mehrotra S, Prajapati VK, Nylen S, Sacks D, et al. (2010) Evaluation of blood agar microtiter plates for culturing leishmania parasites to titrate parasite burden in spleen and peripheral blood of patients with visceral leishmaniasis. J Clin Microbiol 48: 1932–1934.
41. Ostyn B, Gidwani K, Khanal B, Picado A, Chappuis F, et al. (2011) Incidence of symptomatic and asymptomatic Leishmania donovani infections in high-endemic foci in India and Nepal: a prospective study. PLoS Negl Trop Dis 5: e1284.
42. Hasker E, Malaviya P, Gidwani K, Picado A, Ostyn B, et al. (2014) Strong association between serological status and probability of progression to clinical visceral leishmaniasis in prospective cohort studies in India and Nepal. PLoS Negl Trop Dis 8: e2657.
43. Badaro R, Benson D, Eulalio MC, Freire M, Cunha S, et al. (1996) rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis 173: 758–761.
44. Sinha PK, Bimal S, Pandey K, Singh SK, Ranjan A, et al. (2008) A community-based, comparative evaluation of direct agglutination and rK39 strip tests in the early detection of subclinical Leishmania donovani infection. Ann Trop Med Parasitol 102: 119–125.
45. ter Horst R, Tefera T, Assefa G, Ebrahim AZ, Davidson RN, et al. (2009) Field evaluation of rK39 test and direct agglutination test for diagnosis of visceral leishmaniasis in a population with high prevalence of human immunodeficiency virus in Ethiopia. Am J Trop Med Hyg 80: 929–934.
46. Nigro L, Vinci C, Romano F, Russo R, (1996) Comparison of the indirect immunofluorescent antibody test and the direct agglutination test for serodiagnosis of visceral leishmaniasis in HIV-infected subjects. Eur J Clin Microbiol Infect Dis 15: 832–835.
47. Kubar J, Marty P, Lelievre A, Quaranta JF, Staccini P, et al. (1998) Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts. AIDS 12: 2147–2153.
48. Ali A, Ashford RW, (1994) Visceral leishmaniasis in Ethiopia. IV. Prevalence, incidence and relation of infection to disease in an endemic area. Ann Trop Med Parasitol 88: 289–293.
49. Khalil EA, Zijlstra EE, Kager PA, El Hassan AM, (2002) Epidemiology and clinical manifestations of Leishmania donovani infection in two villages in an endemic area in eastern Sudan. Trop Med Int Health 7: 35–44.
50. Zijlstra EE, el-Hassan AM, Ismael A, Ghalib HW, (1994) Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg 51: 826–836.
51. Turgay N, Balcioglu IC, Toz SO, Ozbel Y, Jones SL, (2010) Quantiferon-Leishmania as an epidemiological tool for evaluating the exposure to Leishmania infection. Am J Trop Med Hyg 83: 822–824.
52. Guan SP, Mok YK, Koo KN, Chu KL, Wong WS, (2009) Chitinases: biomarkers for human diseases. Protein Pept Lett 16: 490–498.
53. Ettinger NA, Wilson ME, (2008) Macrophage and T-cell gene expression in a model of early infection with the protozoan Leishmania chagasi. PLoS Negl Trop Dis 2: e252.
54. Bittar RC, Nogueira RS, Vieira-Goncalves R, Pinho-Ribeiro V, Mattos MS, et al. (2007) T-cell responses associated with resistance to Leishmania infection in individuals from endemic areas for Leishmania (Viannia) braziliensis. Mem Inst Oswaldo Cruz 102: 625–630.
55. Hailu A, van Baarle D, Knol GJ, Berhe N, Miedema F, et al. (2005) T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. Clin Immunol 117: 182–191.
56. Ajdary S, Riazi-Rad F, Jafari-Shakib R, Mohebbali M, (2006) Soluble CD26/CD30 levels in visceral leishmaniasis: markers of disease activity. Clin Exp Immunol 145: 44–47.
57. Hamerlinck FF, van Gool T, Faber WR, Kager PA, (2000) Serum neopterin concentrations during treatment of leishmaniasis: useful as test of cure? FEMS Immunol Med Microbiol 27: 31–34.
58. Moller HJ, (2012) Soluble CD163. Scand J Clin Lab Invest 72: 1–13.
59. Stober CB, Jeronimo SM, Pontes NN, Miller EN, Blackwell JM, (2012) Cytokine responses to novel antigens in a peri-urban population in Brazil exposed to Leishmania infantum chagasi. Am J Trop Med Hyg 87: 663–670.
60. Medrano FJ, Rey C, Leal M, Canavate C, Rubio A, et al. (1998) Dynamics of serum cytokines in patients with visceral leishmaniasis and HIV-1 co-infection. Clin Exp Immunol 114: 403–407.
61. Nylen S, Sacks D, (2007) Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 28: 378–384.
62. Chaussabel D, Pascual V, Banchereau J, (2010) Assessing the human immune system through blood transcriptomics. BMC Biol 8: 84.
63. Fontana JM, Alexander E, Salvatore M, (2012) Translational research in infectious disease: current paradigms and challenges ahead. Transl Res 159: 430–453.
64. Jacobsen M, Repsilber D, Gutschmidt A, Neher A, Feldmann K, et al. (2007) Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med (Berl) 85: 613–621.
65. Kaforou M, Wright VJ, Oni T, French N, Anderson ST, et al. (2013) Detection of Tuberculosis in HIV-Infected and -Uninfected African Adults Using Whole Blood RNA Expression Signatures: A Case-Control Study. PLoS Med 10: e1001538.
66. CDC (2013) Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.
67. van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, et al. (2010) Combination therapy for visceral leishmaniasis. Lancet Infect Dis 10: 184–194.
68. Barragan P, Lopez-Velez R, Olmo M, Podzamczer D, (2010) Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. Am J Trop Med Hyg 83: 10–12.
69. Torrus D, Boix V, Massa B, Portilla J, Perez-Mateo M, (1996) Fluconazole plus allopurinol in treatment of visceral leishmaniasis. J Antimicrob Chemother 37: 1042–1043.
70. Angarano G, Maggi P, Coppola SL, Cavaliere RL, (1998) Itraconazole as maintenance therapy for visceral leishmaniasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 17: 365–367.
71. Lafeuillade A, Chaffanjon P, Delbeke E, Quilichini R, (1992) Maintenance itraconazole for visceral leishmaniasis in HIV infection. Am J Med 92: 449.
72. Mukherjee S, Mukherjee B, Mukhopadhyay R, Naskar K, Sundar S, et al. (2012) Imipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infection. PLoS Negl Trop Dis 6: e1987.
73. Wyllie S, Patterson S, Stojanovski L, Simeons FR, Norval S, et al. (2012) The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Sci Transl Med 4: 119re111.
74. Chatelain E, Ioset JR, (2011) Drug discovery and development for neglected diseases: the DNDi model. Drug Des Devel Ther 5: 175–181.
75. Hide M, Marion E, Pomares C, Fisa R, Marty P, et al. (2013) Parasitic genotypes appear to differ in leishmaniasis patients compared with asymptomatic related carriers. Int J Parasitol 43: 389–397.
76. WHO (2006) Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach, 2006 Revision. Geneva: Word Health Organization.
77. WHO (2006) Guidelines on co-trimoxazole prophylaxis for HIV-related infection among children, adolescents and adults: recommendations for a public health approach. Geneva: World Health Organization.
78. Bogdan C, (2008) Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell Microbiol 10: 1221–1234.
79. Zandieh A, Zandieh B, Dastgheib L, (2013) Dissemination of localized cutaneous leishmaniasis in an organ transplant recipient: case report and literature review. Int J Dermatol 52: 59–62.
80. Seden K, Khoo S, Back D, Prevatt N, Lamorde M, et al. (2013) Drug-drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical Diseases. AIDS 27: 675–686.